Fig. 5. Erlotinib increases pYAP and suppresses YAP/TAZ-regulated genes.

a Immunoblot of pEGFR (Y1068), EGFR, pYAP (S127), YAP, β-actin in WSU-HN6 and HCC827 cells. Cells were treated with erlotinib at the indicated concentrations for 2 h. b Relative mRNA levels of CTGF, CYR61, and AMOTL2 in WSU-HN6 and HCC827 cells. Cells were treated with erlotinib (1 μM) for 2 h. c The top 15 enriched oncogenic signatures gene sets from RNA-seq data analysis of HCC827 cells. YAP-regulated signatures gene sets are highlighted in red. Cells were treated with vehicle or erlotinib (1 μM) for 24 h. The original name of signature gene sets are listed in supplementary Fig. S5a. d Heat map showing Z-score normalized mRNA expression of representative YAP/TAZ-regulated genes highlighted in orange and yellow. The genes highlighted in green and blue are consistent with the ones previously reported as up- or downregulated by erlotinib treatment³¹. e Enrichment plots of YAP conserved signatures. f Immunoblot of YAP, TAZ, β-actin in HN6 and HCC827 cells. Cells were transfected with siRNA for control and YAP/TAZ, and incubated for 48 h. g Cell viability. ANOVA with Tukey–Kramer post hoc test and Student’s t-test were used. Mean ± SEM (b, g); ***P <0.001; **P <0.01.